US › Healthcare

Biodesix Inc (BDSX)

US · Healthcare · Diagnostics & Research

$22.75+3.29%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$25.6M
Revenue YoY
+42.3%
Net profit
$-7.8M
Profit YoY
+29.8%
EPS
$-0.81
EPS estimate
$-1.10
Net margin
-30.5%

EPS came in at -0.81 against a street estimate of -1.10 — a beat of 26.4%.

Key statistics

Market cap
$228.1M
Forward P/E
0.0
P/B
23.97
Book value
$0.90
EPS (TTM)
$-3.96
52-week high
$24.91
52-week low
$5.26
50-day MA
$18.74
200-day MA
$12.74
Beta
0.56

Analyst view

Analysts rate Biodesix Inc a strong buy (5 buy, 1 hold, 0 sell out of 6) with an average price target of $30.83.

Shareholding

Insiders
40.89%
Institutions
39.11%

Largest institutional holders

FundStake
AIGH Capital Management, LLC7.32%
Telemark Asset Management, LLC4.73%
Aberdeen Group PLC4.43%
Soleus Capital Management, L.P.4.02%
Vanguard Capital Management, LLC2.46%
Opaleye Management Inc2.30%
Marshall Wace Asset Management Ltd1.37%
StemPoint Capital LP1.35%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Biodesix Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.